Background: The efficacy of programmed death-1 blockade in epidermal growth factor receptor gene (EGFR) mutationpositive non-small-cell lung cancer (NSCLC) patients with different mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors (TKIs) is unknown. We retrospectively evaluated nivolumab efficacy and immune-related factors in such patients according to their status for the T790M resistance mutation of EGFR.
Introduction
Lung cancer is the most common cause of cancer deaths worldwide [1] . The advent of molecular profiling has led to the discovery of 'driver mutations' and to targeted therapy and personalized medicine for lung cancer. Mutations of the epidermal growth factor receptor gene (EGFR) are common drivers of non-small-cell lung cancer (NSCLC) [2] . EGFR tyrosine kinase inhibitors (TKIs) are considered the best choice for first-line treatment of advanced or recurrent nonsquamous NSCLC harboring activating mutations of EGFR [2] . However, individuals treated with EGFR-TKIs eventually develop resistance to these drugs, most commonly as the result of a secondary T790M mutation of EGFR. Osimertinib, a third-generation EGFR-TKI, confers a survival benefit compared with cytotoxic chemotherapy in such T790M-positive patients [3] . The optimal treatment of T790M-negative patients who develop EGFR-TKI resistance remains unclear, however, with such individuals appearing to have a poorer prognosis compared with T790M-positive patients [4] . A more efficacious treatment strategy for T790M-negative patients is thus needed.
Monoclonal antibodies to programmed death-1 (PD-1), such as nivolumab and pembrolizumab, prolong overall survival (OS) compared with docetaxel in NSCLC patients previously treated with platinum-doublet chemotherapy [5, 6] . However, subgroup analysis of clinical trials has suggested that PD-1 inhibitor therapy is less effective for patients with EGFR mutations than for those wild-type for EGFR [5] [6] [7] . In addition, a retrospective study found that EGFR mutation positivity in NSCLC was associated with a low overall response rate (ORR) to PD-1 inhibitors and that low levels of both programmed death-ligand 1 (PD-L1) and CD8 þ tumor-infiltrating lymphocytes (TILs) within the tumor microenvironment might underlie this unfavorable clinical response [8] . Moreover, little is known of the relation between PD-1 inhibitor efficacy and the mechanism of acquired resistance to EGFR-TKIs.
We have now carried out a retrospective study to evaluate the efficacy of nivolumab according to T790M status in patients with EGFR mutation-positive NSCLC after the development of resistance to EGFR-TKIs. The expression level of PD-L1 and density of TILs (CD8 þ , CD4 þ , or FOXP3 þ cells) were also examined in tumor tissue specimens obtained after the development of EGFR-TKI resistance. In addition, we carried out whole-exome sequencing of tumor DNA.
Patients and methods

Patients
We reviewed the medical records of all patients with advanced or recurrent EGFR mutation-positive NSCLC treated at Kindai University Hospital, Kishiwada City Hospital, or Kurashiki Central Hospital between February 2012 and August 2016. EGFR mutations were detected with commercial assays such as the Cobas EGFR Mutation Test (Roche Molecular Diagnostics). Analysis of plasma cell-free DNA was allowed for determination of T790M status after the development of EGFR-TKI resistance if tumor tissue specimens were unavailable. The study was carried out according to protocols approved by the Institutional Review Board of each participating hospital.
From this review, we identified 25 such patients who were assessed for T790M status after disease progression during treatment with at least one EGFR-TKI and who were treated with nivolumab monotherapy thereafter (cohort A). The clinical outcome of nivolumab treatment was analyzed, and immunohistochemical analysis and whole-exome sequencing were carried out with formalin-fixed paraffin-embedded (FFPE) tumor tissue obtained after the development of EGFR-TKI resistance. In addition, we identified an independent cohort of 60 patients with EGFR mutation-positive NSCLC who had sufficient FFPE tumor tissue collected after progression on EGFR-TKIs for immunohistochemistry (cohort B).
Data collection
Medical records were reviewed, and data regarding clinicopathologic features and treatment history were extracted. Data were updated as of 31 December 2016. Responses were assessed according to RECIST v1.1 [9] . Progression-free survival (PFS) was measured from treatment initiation to clinical or radiographic progression or death from any cause. OS was measured from treatment initiation to death from any cause. Patients without documented clinical or radiographic disease progression or who were still alive were censored on the date of last follow-up.
Immunohistochemistry
Tumor histology was classified according to WHO criteria [10] . Immunohistochemistry was carried out with monoclonal antibodies to PD-L1 (clone 28-8, Abcam), to CD8 (clone C8/144B, Agilent Technologies), to CD4 (clone 1F6, Leica Biosystems), and to FOXP3 (clone 236A/E7, Abcam) and with the use of an automated stainer (Leica Bond-III). The stained slides were scanned with an Aperio Scan Scope (Leica Biosystems) and were evaluated by board-certified pathologists who were blinded to clinical outcome. Further details are provided in supplementary methods, supplementary Figure S1 , supplementary Figure S2 , available at Annals of Oncology online.
Whole-exome sequencing and exome analysis pipeline 
Statistical analysis
See supplementary methods, available at Annals of Oncology online.
Results
Outcome of nivolumab treatment of EGFR mutation-positive NSCLC patients according to T790M status and PD-L1 expression level (cohort A)
The characteristics of the 25 patients of cohort A are listed in Table 1 . Eight patients were positive for T790M, with four patients being tested for this mutation with plasma cell-free DNA. Six of the T790M-positive patients were treated with a thirdgeneration EGFR-TKI during their disease course, four of which were after disease progression on nivolumab treatment.
For the entire cohort, the ORR was 20% and the disease control rate (DCR) was 36% (supplementary Table S1 , available at Annals of Oncology online). The ORR (24% versus 13%, P ¼ 1.000) and DCR (47% versus 13%, P ¼ 0.182) were higher in the T790M-negative patients than in the T790M-positive patients. The median PFS for the entire cohort was 1.5 months [95% confidence interval (CI), 1.3-2.8] ( Figure 1A ). The median PFS was 2.1 months (95% CI, 1.3-3.4) and 1.3 months (95% CI, 0.1-1.8) for T790M-negative and T790M-positive patients (P ¼ 0.099), respectively, with the hazard ratio (HR) being 0.48 (95% CI, 0.20-1.24) ( Figure 1B ). The outcome of nivolumab treatment thus tended to be more favorable in T790M-negative patients than in T790M-positive patients.
We next evaluated nivolumab efficacy according to PD-L1 expression level and TIL density in tumor tissue, which were evaluable in 15 and 14 of the 25 patients, respectively. The ORR increased as the PD-L1 expression level increased (38%, 75%, and 100% in patients with a PD-L1 expression level of 1%, 10%, or 50%, respectively) (supplementary Table  S1 , available at Annals of Oncology online). The median PFS was also longer in patients with a PD-L1 expression level of 1% than in those with a level of <1% (2.1 versus 1.3 months, P ¼ 0.084) (Figure 2A ), with the HR being 0.37 (95% CI, 0.10-1.21). A trend toward a better PFS was apparent as the PD-L1 expression level increased at cutoff values of 10% and 50% (supplementary Figure S3 , available at Annals of Oncology online). The proportion of individuals with a PD-L1 expression level of 1% was similar for T790M-positive and T790M-negative patients, but the proportion of those with PD-L1 expression levels of 10% or 50% Current smokers were defined as individuals who had smoked a cigarette within the previous year; former smokers were defined as those who had smoked 100 cigarettes but had quit >1 year before rebiopsy; never-smokers were defined as individuals who had smoked <100 cigarettes. c One patient had Ex19del and T790M, and two patients had L858R and T790M. Two patients had G719A, one patient had G719C, one patient had L861Q, and one patient had G719S and L861Q. e T790M status for four of these patients was determined by analysis of plasma cell-free DNA. ECOG PS, Eastern Cooperative Oncology Group performance status; CNS, central nervous system; TKI, tyrosine kinase inhibitor; EGFR, epidermal growth factor receptor; Ex19del, exon 19 deletion; PFS, progression-free survival. ) (E). Scales bars, 100 mm.
was higher for T790M-negative patients than for T790M-positive patients ( Table 2 ). The Wilcoxon rank sum test revealed that the CD8 þ TIL count was significantly (P ¼ 0.024) higher in nivolumab responders than in nonresponders ( Figure 2B ). In contrast, the numbers of CD4 þ TILs and FOXP3 þ TILs were not associated with nivolumab efficacy ( Figure 2C and D) . The FOXP3 þ TIL count was highest (373/mm 2 ) for a T790M-negative patient who had a PD-L1 expression level of 10% and a high CD8 þ TIL count (1727/ mm 2 ) but who did not respond to nivolumab (arrows in Figure 2B and D). Representative immunohistochemistry images for a T790M-negative patient who showed a response to nivolumab and had a high PD-L1 expression level (50%), high CD8 Figure 2E , whereas those for the nonresponder with the highest FOXP3 þ TIL count are shown in Figure 2F . The numbers of CD8 þ TILs and FOXP3 þ TILs were similar for T790M-positive and T790M-negative patients in this cohort (Table 2) .
Although the median OS was not achieved at a median followup of 7.3 months for all patients in cohort A, the HR for OS was 0.38 (95% CI, 0.09-1.65) for the T790M-negative group versus the T790M-positive group (supplementary Figure S4 , available at Annals of Oncology online), suggestive of a survival benefit of nivolumab treatment in T790M-negative patients.
PD-L1 expression level and TIL density according to T790M status after EGFR-TKI treatment (cohort B)
To validate our finding that the PD-L1 expression level was higher in T790M-negative patients of cohort A, we evaluated such expression in an independent cohort (cohort B) ( Table 1) . We also determined CD8 þ TIL density and FOXP3 þ TIL density in this cohort. All tumor specimens were obtained by biopsy after disease progression during EGFR-TKI treatment. Six, seven, and eight patients could not be evaluated for PD-L1 expression, CD8 þ TIL density, or FOXP3 þ TIL density, respectively.
The proportion of individuals with a PD-L1 expression level of 1% was similar for both T790M-positive and T790M-negative patients, whereas the proportion of those with a PD-L1 expression level of 10% or 50% was higher for T790M-negative patients than for T790M-positive patients ( Table 2 ). The number of CD8 þ TILs was similar for T790M-positive and T790M-negative patients, although there was a more frequent coexistence of a high PD-L1 expression level (10% or 50%) and a high CD8 þ TIL count (more than or equal to the median) in the T790M-negative group than in the T790M-positive group [5/25 (20%) versus 1/24 (4%) and 3/25 (12%) versus 1/24 (4%), respectively]. The FOXP3 þ TIL count was significantly (P ¼ 0.013) lower in T790M-negative than in T790M-positive patients of cohort B.
Whole-exome sequencing analysis
To investigate the relation of nonsynonymous mutation burden to nivolumab efficacy in EGFR mutation-positive NSCLC, we carried out whole-exome sequencing for nine patients (three responders and six nonresponders) of cohort A (Table 3 ). The median nonsynonymous mutation burden per tumor was 101. The burden was significantly (P ¼ 0.038) higher in responders than in nonresponders, but it did not differ (P ¼ 0.71) between T790M-negative and T790M-positive patients. Two of the five T790M-negative patients were positive for KRAS(G13D) or PIK3CA (E545K) mutations, both of which are thought to confer resistance to EGFR-TKIs. In addition, comparative copy number analysis revealed a significant copy number gain for MET in another two of the T790M-negative patients who also expressed PD-L1 at a high level (50%) and responded to nivolumab treatment.
Discussion
Our results have revealed that nivolumab efficacy after disease progression during EGFR-TKI treatment tended to be greater for EGFR mutation-positive NSCLC patients negative for T790M Fisher's exact test or Wilcoxon rank sum test for PD-L1 expression level and TIL density, respectively. PD-L1, programmed death-ligand 1; TIL, tumor-infiltrating lymphocyte; EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor.
than for those positive for this resistance mutation, likely as a result of a higher PD-L1 expression level in the T790M-negative group. Analysis of an independent cohort confirmed a higher level of PD-L1 expression in T790M-negative patients compared with those positive for T790M. Our study is the first to examine the relation of the tumor immune microenvironment to the efficacy of a PD-1 inhibitor in EGFR mutation-positive NSCLC according to T790M status after disease progression during EGFR-TKI treatment. Previous studies have indicated that PD-1 inhibition is a promising treatment strategy for tumors that overexpress c-MET or have undergone epithelial-to-mesenchymal transition, both of which constitute mechanisms of resistance to EGFR-TKIs [11] [12] [13] . Consistent with these previous findings, our wholeexome sequencing analysis revealed that two nivolumab responders with a high level of PD-L1 expression manifested a copy number gain for MET. The specific mechanisms that underlie the relation between EGFR-TKI resistance in T790M-negative tumors and PD-L1 expression warrant further study. CD8 þ TIL density is a predictive marker for the efficacy of PD-1 inhibitors [8] . We found that the CD8 þ TIL count was significantly higher in nivolumab responders with EGFR mutationpositive NSCLC. Although the CD8 þ TIL density did not differ between T790M-positive and T790M-negative patients, there was a more frequent coexistence of a high PD-L1 expression level and a high CD8
þ TIL count in T790M-negative patients, consistent with the notion that such patients are potential candidates for PD-1 inhibitor therapy.
Nonsynonymous mutation burden is emerging as a predictive marker for the efficacy of PD-1 blockade [14] . EGFR mutationpositive NSCLC including that positive for T790M has previously been shown to have a low mutation burden by whole-exome sequencing [15] , suggesting that PD-1 inhibitors might not be appropriate for such tumors. On the other hand, the mechanism of EGFR-TKI resistance in T790M-negative tumors is molecularly heterogeneous [16] , leaving open the possibility that mutation burden may be higher in some of these tumors. Our findings suggest that a subset of EGFR mutation-positive NSCLC patients with acquired resistance to EGFR-TKIs may have a relatively high nonsynonymous mutation burden and therefore benefit from PD-1 inhibitor treatment, although there was no clear difference in mutation burden based on T790M status, possibly as a result of our small sample size.
The role of FOXP3 þ TILs in PD-1 blockade therapy has been unclear. Although we did not detect a clear relation between nivolumab efficacy and FOXP3 þ TIL density, our immunohistochemical findings in individual patients hinted that FOXP3 þ TILs might contribute to resistance to PD-1 inhibitors ( Figure  2F ). Inhibitors of regulatory T cells such as FOXP3
þ TILs, including CTLA-4 inhibitors, are considered candidates for combination therapy with PD-1 inhibitors in PD-L1-positive NSCLC patients with EGFR mutations [17] . Indeed, the CheckMate 012 trial showed that combination therapy with nivolumab and ipilimumab was effective (ORR of 50%) in a small cohort of patients with EGFR mutation-positive NSCLC [18] .
There are several limitations to our study. The study was thus retrospective in nature and the number of patients was small, making it difficult to draw definitive conclusions. Multivariate analysis could not be carried out because of the small number of patients, leaving open the possibility for bias in the clinical data. Nevertheless, given that our study is the first to report that T790M-negative status tended to be associated with a more favorable efficacy of a PD-1 inhibitor, likely as a result, at least in part, of a higher PD-L1 expression level, our findings may prove helpful for clinical decision-making regarding the use of PD-1 inhibitors in patients with EGFR mutation-positive NSCLC. PD-1 inhibitors may thus be more promising therapeutic agents for T790M-negative patients, especially those positive for PD-L1, after disease progression during EGFR-TKI treatment, whereas osimertinib has been recognized as the first treatment choice for T790M-positive patients. Prospective clinical trials are required to confirm the efficacy of PD-1 inhibitors in T790M-negative EGFR, epidermal growth factor receptor; Ex19del, exon 19 deletion; TKI, tyrosine kinase inhibitor; PFS, progression-free survival; PD-L1, programmed death-ligand 1; NMB, nonsynonymous mutation burden; amp, amplification. Nonsynonymous mutation burden differed significantly between responders to nivolumab treatment and nonresponders (P ¼ 0.038, Wilcoxon rank sum test), but not between T790M-negative and T790M-positive patients (P ¼ 0.71).
patients with EGFR mutation-positive NSCLC. The WJOG8515L study, a randomized phase II trial to compare nivolumab with platinum-doublet therapy in patients with EGFR mutation-positive nonsquamous NSCLC who have developed resistance to EGFR-TKIs due to mechanisms other than T790M is currently in progress (UMIN-CTR ID: UMIN000021133).
In conclusion, our findings suggest that EGFR mutation-positive NSCLC patients with acquired resistance to EGFR-TKIs not due to T790M are more likely to receive benefit from PD-1 inhibitors than are those positive for this resistance mutation, possibly as a result of a higher PD-L1 expression level in the T790M-negative patients. Prospective clinical trials are warranted to confirm these results.
